EYPT vs OCUL vs RCKT

For growth investors, Ocular Therapeutix, Inc.

(OCUL) is the stronger pick with -18. 7% revenue growth year-over-year, versus -27. 5% for EyePoint Pharmaceuticals, Inc. (EYPT). Analysts rate EyePoint Pharmaceuticals, Inc. (EYPT) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, EyePoint Pharmaceuticals, Inc.

(EYPT) delivered a total return of +37. 7%, compared to -91. 6% for Rocket Pharmaceuticals, Inc. (RCKT). Over 10 years, the gap is even starker: OCUL returned -10. 6% versus RCKT's -91. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), EyePoint Pharmaceuticals, Inc.

(EYPT) is the lower-risk stock at 1. 20β versus Rocket Pharmaceuticals, Inc. 's 1. 31β — meaning RCKT is approximately 10% more volatile than EYPT relative to the S&P 500. On balance sheet safety, EyePoint Pharmaceuticals, Inc. (EYPT) carries a lower debt/equity ratio of 7% versus 12% for Ocular Therapeutix, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ocular Therapeutix, Inc.

(OCUL) is pulling ahead at -18. 7% versus -27. 5% for EyePoint Pharmaceuticals, Inc. (EYPT). On earnings-per-share growth, the picture is similar: Rocket Pharmaceuticals, Inc. grew EPS 26. 4% year-over-year, compared to -36. 6% for EyePoint Pharmaceuticals, Inc.. Over a 3-year CAGR, OCUL leads at 0. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Rocket Pharmaceuticals, Inc.

(RCKT) is the more profitable company, earning 0. 0% net margin versus -739. 4% for EyePoint Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCKT leads at 0. 0% versus -776. 0% for EYPT. At the gross margin level — before operating expenses — EYPT leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, EyePoint Pharmaceuticals, Inc.

(EYPT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 20)). Both have compounded well over 10 years (EYPT: -55. 2%, RCKT: -91. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.